Tetramethylputrescine is a polyamine derivative that has been found to have a variety of biological effects. It has been shown to be an inhibitor of polyamine oxidase, an enzyme that breaks down polyamines. Tetramethylputrescine has also been shown to have anti-inflammatory and anti-tumor effects. It is being studied for its potential therapeutic uses in a variety of diseases, including cancer, arthritis, and Alzheimer's disease.'
tetramethylputrescine: RN given refers to 1,4-amine cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 66074 |
| SCHEMBL ID | 21216 |
| MeSH ID | M0054129 |
| Synonym |
|---|
| tetramethyldiaminobutane |
| 1,4-bis(dimethylamino)butane |
| brn 1735538 |
| n,n,n',n'-tetramethyl-1,4-butanediamine |
| einecs 203-878-5 |
| n,n,n',n'-tetramethyl-1,4'-butanediamine |
| tetramethylputrescine |
| ai3-23335 |
| alpha,delta-(tetramethyldiamino)butane |
| n,n,n',n'-tetramethyltetramethylenediamine |
| .alpha.,.delta.-(tetramethyldiamino)butane |
| 1,4-butanediamine, n,n,n',n'-tetramethyl- |
| 111-51-3 |
| n,n,n',n'-tetramethyl-1,4-butanediamine, 98% |
| n,n,n',n'-tetramethylbutane-1,4-diamine |
| inchi=1/c8h20n2/c1-9(2)7-5-6-8-10(3)4/h5-8h2,1-4h3 |
| veazepmqwhphag-uhfffaoysa- |
| T1289 |
| n,n,n',n'-tetramethyl-1,4-diaminobutane |
| unii-5j7765fhlu |
| 5j7765fhlu , |
| 4-04-00-01284 (beilstein handbook reference) |
| 1,4-butanediamine, n1,n1,n4,n4-tetramethyl- |
| FT-0606798 |
| AKOS015894497 |
| n,n,n',n'-tetramethylputrescine |
| n(sup1),n(sup1),n(sup4),n(sup4)-tetramethyl-1,4-butanediamine |
| tetramethyldiaminobutane [mi] |
| n,n,n,n-tetramethyl-1,4-butanediamine |
| SCHEMBL21216 |
| n,n,n',n'-tetramethylbutylenediamine |
| (ch3)2n(ch2)4n(ch3)2 |
| 2,7-dimethyl-2,7-diazaoctane |
| DTXSID0059403 |
| mfcd00008338 |
| tetramethylputrescin |
| n1,n1,n4,n4-tetramethylbutane-1,4-diamine |
| J-640337 |
| J-800340 |
| n,n,n',n'-tetramethyl-butane-1,4-diamine |
| Q27262400 |
| D94769 |
| AS-75485 |
| CS-0095543 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.38) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||